Shukra Pharmaceuticals Ltd. has scheduled an Extra-Ordinary General Meeting (EGM) on July 6, 2026, at 12:00 p.m. via Video Conferencing to seek shareholder approval for the preferential allotment of 46,43,000 Convertible Equity Warrants at a revised price of ₹35.56 per warrant. The issue aggregates to ₹16,51,05,080 and targets the promoter category to raise capital. The price revision was necessitated by a delay in allotment following the original approval, requiring a fresh Special Resolution under Regulation 170(2) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The Board of Directors approved the proposal on June 10, 2026. The warrants carry a right to subscribe to one Equity Share per warrant and have a tenure not exceeding 18 months from the date of allotment. The Board determined the Relevant Date for pricing as June 5, 2026, which is 30 days prior to the proposed EGM. The issue price is set at the higher of the previously approved ₹34 per warrant or the re-computed price of ₹35.56 per warrant. An amount equivalent to 25% of the original warrant issue price has already been received from the proposed allottees.

Ms. Rupal Patel, Practicing Company Secretary, was appointed as the Scrutinizer to ensure the voting process is conducted fairly. The meeting outcome was submitted to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Preferential Allotment Details

Shareholding Pattern Post-Allotment

Shukra Pharmaceuticals Limited's Board of Directors, at its meeting held on May 7, 2026, approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The results were reviewed by the Audit Committee and audited by M/s Shah Sanghvi and Associates, Chartered Accountants (FRN: 140107W), who issued an unmodified audit opinion. Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited standalone financial results for the fourth quarter and financial year ended March 31, 2026 were subsequently published in Business Standard (English) and Jai Hind (Gujarati) newspapers. The board meeting commenced at 6.00 p.m. and concluded at 10.00 p.m.

Standalone Financial Performance

On a standalone basis, Shukra Pharmaceuticals delivered a strong full-year performance, with revenue from operations rising significantly year-on-year. The company operates in two segments — "Shukra Pharmaceutical" and "Shukra MedTech" (the latter effective from October 1, 2025). The following table summarises the key standalone financial metrics (all amounts in ₹ Lakhs):

For the full year FY26, standalone revenue from operations stood at ₹5,670.61 lakhs compared to ₹3,258.73 lakhs in FY25. Net profit for FY26 was ₹2,204.79 lakhs, compared to ₹957.51 lakhs in FY25. For the quarter ended March 31, 2026, the company reported a net loss of ₹172.67 lakhs, primarily on account of higher tax expenses including current tax of ₹442.63 lakhs during the quarter.

Q4 EBITDA Performance

On a standalone basis for Q4, key operating metrics reflected a sharp year-on-year contraction. The table below presents the Q4 EBITDA and related metrics as reported:

The Q4 EBITDA margin contracted sharply to 10.91% from 55.16% in the same quarter of the previous year, while EBITDA declined to 6.9M rupees from 73M rupees year-on-year. Revenue for the quarter also declined to 63M rupees from 133M rupees in Q4 FY25, and the company swung to a net loss of 17M rupees compared to a net profit of 54M rupees in the year-ago period.

Consolidated Financial Performance

On a consolidated basis, which includes subsidiaries — Shukra Diabetes Technologies Private Limited, Shukra Health Tech Private Limited, Shukra Robotics Private Limited, and Shukra Woundcare Private Limited — the company reported the following results (all amounts in ₹ Lakhs):

The four subsidiaries included in the consolidated results had unaudited interim financials reflecting total revenues of Rs. 2.12 lakhs, total net profit after tax of Rs. 1.04 lakhs, and total comprehensive profit of Rs. 1.04 lakhs for the period from April 1, 2025 to March 31, 2026.

Balance Sheet Highlights

The standalone balance sheet as at March 31, 2026 reflects total assets of ₹11,741.39 lakhs, compared to ₹8,677.32 lakhs as at March 31, 2025. Total equity stood at ₹8,983.25 lakhs versus ₹6,283.59 lakhs in the prior year. On a consolidated basis, total assets were ₹11,744.00 lakhs and total equity was ₹8,984.90 lakhs as at March 31, 2026. Key balance sheet items are summarised below (all amounts in ₹ Lakhs):

Dividend Recommendation

The Board recommended a Final Dividend of Rs. 0.01/- (1%) per equity share of Re. 1/- each fully paid for the financial year 2025-26, subject to deduction of tax, if any. This dividend is subject to approval by shareholders at the ensuing Annual General Meeting.

Warrant Conversion and Share Allotment

The Board approved the allotment of 17,35,000 fully paid-up equity shares of face value Re. 1/- each to promoter warrant holders — Dakshesh Shah and Parshva Texchem India Private Limited — upon exercise of their right to convert share warrants into equity shares. The allotment was made for cash, upon receipt of the remaining exercise price of Rs. 25.50/- per share warrant (being 75% of the warrant exercise price of Rs. 34/- per warrant), aggregating to Rs. 4,42,42,500/-.

Details of the warrant conversion are as follows:

Consequent to this allotment, the paid-up equity capital of the company increased from Rs. 43,78,79,440/- (consisting of 43,78,79,440 equity shares of Re. 1/- each) to Rs. 43,96,14,440/- (consisting of 43,96,14,440 equity shares of Re. 1/- each). Of the total 46,43,000 warrants allotted on November 01, 2025, 29,08,000 warrants remain outstanding for conversion. These warrant holders are entitled to convert their warrants into an equal number of equity shares by paying the remaining 75% (Rs. 25.50/- per warrant) within 18 months from the date of warrant allotment. The company confirmed there is no deviation or variation in the utilization of proceeds from the preferential issue of convertible warrants, as reviewed by the Audit Committee.